Search | Search by Center | Search by Source | Keywords in Title
Suda KJ, Traversa A, Patel U, Poggensee L, Fitzpatrick MA, Wilson GM, Evans CT. Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE). Infection control and hospital epidemiology. 2023 Apr 1; 44(4):674-677.
Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects. We assessed trends in treatment of patients with CRE from 2012 through 2018. We detected decreased utilization of aminoglycosides and colistin and increased utilization in extended-spectrum cephalosporins and ceftazidime-avibactam. We found significant uptake of ceftazidime-avibactam, a newly approved antibiotic, to treat CRE infections.